{"links":{"html":"https://www.erudio.com/reports/artemide-01-nct04995523","json":"https://www.erudio.com/reports/artemide-01-nct04995523.json","markdown":"https://www.erudio.com/reports/artemide-01-nct04995523.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"artemide-01-04995523"}},"request":"https://www.erudio.com/contact?report=artemide-01-04995523"},"offer":{"cited_commentary_sources":15,"verified_hcp_statements":53,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":9,"optional":true,"price_per_verified_person_usd":15,"price_usd":135,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"artemide-01-nct04995523"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=artemide-01-04995523","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/artemide-01-nct04995523","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T02:58:06.826368Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":1},"aspects":[{"claim_count":5,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":5,"title":"Primary endpoint: Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Rate of rilvegostomig discontinuation due to toxicity"},{"claim_count":4,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":3,"title":"Primary endpoint: Objective Response Rate (ORR)"},{"claim_count":6,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":9,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":8,"title":"Population and setting"},{"claim_count":1,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":1,"title":"The comparison"},{"claim_count":5,"coverage":"discussed","id":"T7","registry_field":"outcomesModule","source_count":5,"title":"Safety and tolerability"},{"claim_count":2,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":1,"title":"Design and conduct"},{"claim_count":9,"coverage":"discussed","id":"A1","source_count":6,"title":"TIGIT viability and proposed bispecific/Fc differentiation"},{"claim_count":5,"coverage":"discussed","id":"A2","source_count":4,"title":"Interpretation of the 2023 AZD2936/rilvegostomig response pattern"},{"claim_count":3,"coverage":"discussed","id":"A3","source_count":3,"title":"Further Phase III and ADC-combination development versus established clinical use"},{"claim_count":4,"coverage":"discussed","id":"A4","source_count":3,"title":"Organizational enthusiasm and ownership of reported views"}],"counts":{"cited_sources":16,"claims_by_expression_type":{"comparison":6,"interpretation":22,"opinion":11,"primary_context":4,"question":1,"restatement":5,"uncertainty":2,"unspecified":2},"claims_by_kind":{"objective_result":1,"protocol_statement":2,"publication_statement":20,"source_observation":30},"clinician_statements":10,"evidence_units":43,"findings":7,"organisational_accounts":4,"people_cited":10,"people_identity_verified":9,"people_total":10,"screened_sources":32,"verified_claims":53},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":4},"has_counterview":true,"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":4,"passages":6,"sources":5,"sources_by_kind":{"commentary":4,"publication":1}},"title":"The favorable CPI-naive reading is concentrated in PD-L1-high disease and remains provisional"},{"id":"F2","structure":{"claims":7,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":1,"views":4},"has_counterview":true,"limitations":3,"links":{"context":1,"support":7},"ma_question":true,"named_voices":4,"passages":8,"sources":5,"sources_by_kind":{"commentary":4,"publication":1}},"title":"Low post-CPI response activity receives sharply different interpretations"},{"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":1,"views":2},"has_counterview":true,"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":4,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"Whether rilvegostomig can validate TIGIT remains an explicit controversy"},{"id":"F4","structure":{"claims":9,"claims_by_group":{"comparisons":3,"experience":0,"questions":0,"restated":2,"views":4},"has_counterview":false,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":2,"passages":5,"sources":3,"sources_by_kind":{"commentary":2,"publication":1}},"title":"Cooperative binding and reduced Fc activity are proposed explanations, not demonstrated clinical advantages"},{"id":"F5","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":6},"has_counterview":false,"limitations":2,"links":{"context":3,"support":7},"ma_question":true,"named_voices":4,"passages":9,"sources":5,"sources_by_kind":{"commentary":4,"publication":1}},"title":"Favorable safety language requires cohort-specific severity and uncertainty"},{"id":"F6","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":5},"has_counterview":false,"limitations":3,"links":{"context":1,"support":7},"ma_question":true,"named_voices":1,"passages":6,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"A speaker’s methodological endorsement concerns efficient dose selection, not comparative efficacy"},{"id":"F7","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":0},"has_counterview":false,"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":0,"passages":3,"sources":2,"sources_by_kind":{"media":1,"publication":1}},"title":"The patient-facing eligibility summary leaves prior-immunotherapy requirements unresolved"}],"medical_affairs_question":"What confirmatory evidence would establish clinically meaningful, PD-L1-specific benefit while resolving post-CPI activity and TIGIT-class doubts?","sections":{"analysis":[{"id":"section-1","level":2,"title":"PD-L1-high activity is promising, not yet a broad first-line conclusion"},{"id":"section-2","level":2,"title":"Post-CPI activity: disappointing responses versus meaningful disease control"},{"id":"section-3","level":2,"title":"TIGIT viability remains contested"},{"id":"section-4","level":2,"title":"Mechanistic differentiation is a reason to test, not proof of benefit"},{"id":"section-5","level":2,"title":"Safety enthusiasm must retain severity, cohort and immunogenicity caveats"},{"id":"section-6","level":2,"title":"Dose-selection praise concerns execution and modeled target engagement"},{"id":"section-7","level":2,"title":"Patient-facing eligibility language remains internally unresolved"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, sequential, phase1, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F5","shared_claims":4}],"id":"T1","label":"Primary endpoint: Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters"},{"findings":[],"id":"T2","label":"Primary endpoint: Rate of rilvegostomig discontinuation due to toxicity"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F5","shared_claims":1}],"id":"T3","label":"Primary endpoint: Objective Response Rate (ORR)"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T4","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":3},{"id":"F5","shared_claims":2},{"id":"F7","shared_claims":2}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F7","shared_claims":1}],"id":"T6","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F5","shared_claims":4}],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F6","shared_claims":2}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T02:58:06.826368Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T03:15:10Z","record_hash":"2aaa646e1e3620972cbc495a80a23513aafb69a5f9b7dad449299b39928ab81c","release_hash":"43024ca6008463773f95cd085826a83041f65fa13b62aff9ddd40a8c8ffd2339","report_id":"erudio-nct04995523","run_id":"7e1bd22c-95e6-44f5-be9c-b3d1d4e2e770","schema_version":"5.0","slug":"artemide-01-04995523","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on ARTEMIDE-01 in the sources reviewed for this edition leads to one open question: What confirmatory evidence would establish clinically meaningful, PD-L1-specific benefit while resolving post-CPI activity and TIGIT-class doubts? Its leading findings: (1) the favorable CPI-naive reading is concentrated in PD-L1-high disease and remains provisional. (2) low post-CPI response activity receives sharply different interpretations. (3) whether rilvegostomig can validate TIGIT remains an explicit controversy. 4 more findings follow. 32 sources screened, 16 cited; not all HCPs or all public discussion.","meta_description":"32 sources screened · 53 verified statements (10 from clinicians verified by NPI or staff page) from 16 sources · 7 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-29T03:15:10Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":32},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","2 matching sources (2 X threads) could not be read and are not included.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","20 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are a limited and uneven sample of public discussion; source totals and reposts cannot be interpreted as independent-HCP counts or the prevalence of a view.","Some potentially relevant public posts were unavailable or incompletely assessed. Discussion that did not use recognizable trial or drug names may be missing.","Several named authors’ clinical roles are not established. Source descriptions of credentials or trial involvement do not independently verify clinical qualifications or make trial-associated views external assessments.","The results publication reports CPI-experienced parts A and B. CPI-naive efficacy figures in this report are presented as the figures cited by the relevant commentators, not as findings established by that publication.","Comments from different meetings, post dates, treatment-exposure settings and data cutoffs cannot establish a change of mind or a direct efficacy comparison.","The patient-facing video leaves contradictory prior-immunotherapy requirements unexplained and does not establish a current arm count.","A standalone protocol and an exact AZD2936 regulatory label were not available; no regulatory position is inferred."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":1,"registry":0,"regulatory":0,"x_thread":13,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":15,"results":1},"count":16,"evidence_window":{"end":"2026-08-14","start":"2023-06-04"},"retrieval_snapshot":"2026-10-29T01:17:09.481200Z","timeline":[{"count":2,"week":"2023-W22"},{"count":2,"week":"2023-W23"},{"count":1,"week":"2023-W37"},{"count":1,"week":"2023-W43"},{"count":1,"week":"2023-W48"},{"count":7,"week":"2025-W43"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2026-W33"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT04995523:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04995523:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42574065","quote_policy":"no_derivatives"},{"id":"mcp:bluesky_thread:plc-7znokoomnopskbqdzcynuwu4-3ld4ivnqg7s2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ryo5z53ggbjijxq7nd6ftqjx-3msuy33uwuc2g","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-wdrywaitiypd3xrfkkmzeplh-3ld6vuo53i22c","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7493927833199611904","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665361233027948545:556ccf7b-e450-41e9-99ca-33a81327f344","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665390719614189568:288e5a3b-7a7e-4549-933b-891a13f6ea35","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665435911574675456:9c17a6f1-c149-4617-bec3-873cab92ac02","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1666329850578182147:a1756c56-4f16-46d5-ba92-6c5e4e7ee46a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716844520262787152:9e0d97a2-be43-4a7a-9fda-c04fafefa52a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1729153850094014678:a3db31e2-22d5-4f3a-a31f-e9006f633837","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1730482109394178380:fdcaf8d8-a815-4c7d-bb03-4c784ae23d04","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1746403186255261698:842137c5-e75c-45b4-ac7a-5d9856aabe26","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1833645438043394068:804a00ee-5c23-4a72-b88a-807fb3416ed4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1833977335328206908:7c18b914-640b-4917-913d-d3b44b2739c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1837854899171676488:e191969b-fddb-44f3-835e-29a2fd96aeb7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1867565553302614294:3365d5a7-0a5b-4181-9cc4-beef762b1b64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1877195875287482654:991657b7-3b8a-47d7-a1cc-bf6adae86b9f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980192999804998017:549426f4-d6b2-4ef5-8d4c-cc9ad5ba8e7b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980193661192421856:abf0a094-da14-450b-b219-9c6e7d11d1bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980194522970939472:f5664528-3e4b-426e-a762-8deeb24dbe65","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980194578767684032:05cea229-317d-4845-bc47-e895eb294bb3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980195512759554523:ab797783-2fcd-490a-95c4-b551fbdd61dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980200042033205307:05e3994f-0e29-41f3-a6be-917c08225d35","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981113092047327429:2cba618f-0a0d-4e18-9a5d-680f2a670624","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1986358119316754833:99b24a38-db98-49cb-a6b4-6602811b18b4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2015468778671263939:d92cfb4b-ad88-4bc7-ae8a-ef9588fb867c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088082313598918978:c0a0dd03-42a0-4c5d-bcdc-ee81924fb6a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093335914051489979:c02b6ffb-d345-470c-85ba-1be98f5288e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094470305016406061:8b450519-2eba-4bb0-8569-2e186246bd01","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099848655381622991:5db1a037-a241-4701-b9eb-5e54f0df5952","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114666638544982379:a08ce2d9-7fa4-4f2b-8b8b-092d8c449b91","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Q6FnbVwuDgA","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":27,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":32},"count":32,"evidence_window":{"end":"2026-10-26","start":"2023-06-04"},"retrieval_snapshot":"2026-10-29T01:17:09.481200Z","timeline":[{"count":3,"week":"2023-W22"},{"count":2,"week":"2023-W23"},{"count":1,"week":"2023-W37"},{"count":1,"week":"2023-W43"},{"count":2,"week":"2023-W48"},{"count":1,"week":"2024-W02"},{"count":2,"week":"2024-W37"},{"count":1,"week":"2024-W38"},{"count":3,"week":"2024-W50"},{"count":1,"week":"2025-W02"},{"count":7,"week":"2025-W43"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2026-W04"},{"count":3,"week":"2026-W33"},{"count":1,"week":"2026-W35"},{"count":1,"week":"2026-W36"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: azd2936","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Non-Small-Cell Lung Carcinoma","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"ARTEMIDE-01","aliases":["ARTEMIDE-01","A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC"],"brief_title":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-Small-Cell Lung Carcinoma"],"enrollment":{"count":212,"type":"ACTUAL"},"interventions":[{"name":"AZD2936","synonyms":["Rilvegostomig"],"type":"DRUG"}],"nct_id":"NCT04995523","official_title":"Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-08-28","type":"ESTIMATED"},"primary_endpoints":[{"description":"A DLT is a toxicity defined by the study protocol that occurs from the first dose of study intervention up to the end of the DLT evaluation period that is assessed as clearly unrelated to the primary disease or intercurrent illness.","measure":"Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters","timeFrame":"Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig"},{"description":"Percentage of participants with AEs leading to discontinuation of rilvegostomig","measure":"Rate of rilvegostomig discontinuation due to toxicity","timeFrame":"Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months)"},{"description":"Percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR) according to RECIST v1.1","measure":"Objective Response Rate (ORR)","timeFrame":"Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)"}],"registry_last_updated":"2026-07-14","registry_url":"https://clinicaltrials.gov/study/NCT04995523","short_name":"ARTEMIDE-01","short_name_basis":"registry_acronym","sponsor":"AstraZeneca","start_date":{"date":"2021-09-14","type":"ACTUAL"},"study_design":"interventional, non randomized, sequential, phase1, phase2","study_ids":[{"id":"D7020C00001","type":"sponsor_study_id"},{"domain":"EU CT Number","id":"2023-508262-15-00","type":"registry"},{"id":"2021-000857-23","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}